CAJ | 학술논문

目的：观察多西他赛联合方案（多西他赛+顺铂）和培美曲赛联合方案（培美曲赛+顺铂）对初治的晚期非小细胞肺癌（NSCLC）的疗效和毒副作用。方法57例晚期NSCLC随机分成他赛联合组和培美曲赛组，入选患者接受≥4个周期化疗，比较两组不同化疗方案的近期疗效和毒副作用及1年的生存率。结果多西他赛联合组和培美曲赛联合组近期疗效的有效率分别为34.4%、32.1%，两组中位生存期分别为8.9和9.3个月，1年生存率分别为28.4%和31.5%。两组差异均无统计学意义，P＞0.05。毒副作用主要表现在血液和消化道反应，对症处理均可恢复或耐受。结论多西他赛联合方案和培美曲赛联合方案对晚期NSCLC均有较好的临床疗效，化疗毒副作用主要表现在血液和消化道反应，但均可耐受或恢复。故两种化疗方案均可作为晚期NSCLC的一线治疗方案。
목적：관찰다서타새연합방안（다서타새+순박）화배미곡새연합방안（배미곡새+순박）대초치적만기비소세포폐암（NSCLC）적료효화독부작용。방법57례만기NSCLC수궤분성타새연합조화배미곡새조，입선환자접수≥4개주기화료，비교량조불동화료방안적근기료효화독부작용급1년적생존솔。결과다서타새연합조화배미곡새연합조근기료효적유효솔분별위34.4%、32.1%，량조중위생존기분별위8.9화9.3개월，1년생존솔분별위28.4%화31.5%。량조차이균무통계학의의，P＞0.05。독부작용주요표현재혈액화소화도반응，대증처리균가회복혹내수。결론다서타새연합방안화배미곡새연합방안대만기NSCLC균유교호적림상료효，화료독부작용주요표현재혈액화소화도반응，단균가내수혹회복。고량충화료방안균가작위만기NSCLC적일선치료방안。
Objective To investigate the efifcacy and toxicity of docetaxel-cisplatin regimen and pemetrexed-cisplatin regimen on advanced non-small cell lung cancer. Methods 57 patients with advanced non-small cell lung cancer were divided into the docetaxel-cisplatin and the pemetrexed-cisplatin groups randomly. All the patients accepted intravenous chemotherapy and preponderated over 4 cycles. A clinical observation on short term effectiveness adverse effects and the 1-year survival rate was per-formed in two groups. Results The short term effective rates in the docetaxel-cisplatin group and pemetrexed-cisplatin group were 34.4%、32.1%, respectively. The median survival time was 8.9 and 9.3months, respectively. The 1-year survival rate was 28.4%、31.5%respectively. The short term effectiveness and the 1-year survival state in two groups had no statisti-cally signiifcant difference (P>0.05). In the adverse effects of the treatment, the major cytotoxicity was leukopenia and Nausea/Vomiting in the two groups, which were tolerable. Conclusions Both docetaxel-cisplatin and pemetrexed-cisplatin regimen for advanced non-small cell lung cancer are ef-fective. The side effects of the two regimens are different but all the ad-verse reactions are tolerable. They can become the original chemotherapy for advanced.